Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Research

CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line

Authors: Qi Zheng, Ling-Yu Zhao, Ying Kong, Ke-Jun Nan, Yu Yao, Zi-Jun Liao

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Background

Gastric cancer is a common and highly lethal malignancy in the world, but its pathogenesis remains elusive. In this study, we focus on the biological functions of CDK-associated Cullin1 (CAC1), a novel gene of the cullin family, in gastric cancer, which may help us to further understand the origin of this malignancy.

Methods

The AGS and MGC803 gastric cancer cell lines and the GES-1 gastric mucosa cell line were selected for study. At first, CAC1 expressions of those cell lines were examined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and western blot examinations, then CAC1 small interfering RNA (CAC1-siRNA) were designed and transfected into the AGS cell line with a relatively high level of CAC1. Once CAC1 was silenced, a series of biological characteristics of AGS cells such as cell proliferation, cell cycle, apoptosis, and expressions of apoptosis-related genes (P53, BCL2 and BAX) were determined by MTT, flow cytometry, qRT-PCR and western blot, respectively.

Results

CAC1 expression of AGS or MGC803 was much higher than that of GES-1. After CAC1 expression was effectively depressed by RNA interference in AGS cells, significant cell growth inhibition occurred. Furthermore, the proportion of cells treated with CAC1-siRNA increased in the G1 phase and decreased in the S phase, indicative of G1 cell cycle arrest. More importantly, the proportions of early/late apoptosis in AGS cells were enhanced with cis-diaminedichloroplatinum (cisplatin, CDDP) treatment, but to a higher extent with cisplatin plus CAC1-siRNA. Interestingly, BCL2 mRNA copies showed about a 30% decrease in the cisplatin group, but dropped by around 60% in the cisplatin plus CAC1-siRNA group. Conversely, the P53 mRNA expressions obtained nearly a two-fold increase in the cisplatin group, in addition to a five-fold increase in the cisplatin plus CAC1-siRNA group, and the BAX mRNA levels had almost a two- and four-fold augmentation, respectively. Meanwhile, P53, BAX and BCL2 showed the same alteration patterns in western blot examinations.

Conclusions

CAC1 can promote cell proliferation in the AGS gastric cancer cell line. Moreover, it can prevent AGS cells from experiencing cisplatin-induced apoptosis via modulating expressions of P53, BCL2 and BAX.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
go back to reference Parkin D, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed Parkin D, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
3.
go back to reference Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed
4.
go back to reference Panani AD: Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008, 266: 99-115. 10.1016/j.canlet.2008.02.053.CrossRefPubMed Panani AD: Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008, 266: 99-115. 10.1016/j.canlet.2008.02.053.CrossRefPubMed
5.
go back to reference Kong Y, Nan K, Yin Y: Identification and characterization of CAC1 as a novel CDK2-associated cullin. Cell Cycle. 2009, 8: 3544-3553.CrossRef Kong Y, Nan K, Yin Y: Identification and characterization of CAC1 as a novel CDK2-associated cullin. Cell Cycle. 2009, 8: 3544-3553.CrossRef
7.
go back to reference Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, Zhou J, Li G: Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2011, 42: 375-383. 10.1016/j.humpath.2010.09.003.CrossRefPubMed Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, Zhou J, Li G: Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2011, 42: 375-383. 10.1016/j.humpath.2010.09.003.CrossRefPubMed
8.
go back to reference Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296: 550-553. 10.1126/science.1068999.CrossRefPubMed Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296: 550-553. 10.1126/science.1068999.CrossRefPubMed
9.
go back to reference Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26: 239-257. 10.1038/bjc.1972.33.PubMedCentralCrossRefPubMed Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26: 239-257. 10.1038/bjc.1972.33.PubMedCentralCrossRefPubMed
10.
go back to reference Strasser A, Harris AW, Bath ML, Cory S: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990, 348: 331-333. 10.1038/348331a0.CrossRefPubMed Strasser A, Harris AW, Bath ML, Cory S: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990, 348: 331-333. 10.1038/348331a0.CrossRefPubMed
11.
go back to reference Martin SJ, Green DR: Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol. 1995, 18: 137-153. 10.1016/1040-8428(94)00124-C.CrossRefPubMed Martin SJ, Green DR: Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol. 1995, 18: 137-153. 10.1016/1040-8428(94)00124-C.CrossRefPubMed
12.
go back to reference Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell. 1991, 65: 1097-1098. 10.1016/0092-8674(91)90002-G.CrossRefPubMed Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell. 1991, 65: 1097-1098. 10.1016/0092-8674(91)90002-G.CrossRefPubMed
14.
go back to reference Thomadaki H, Scorilas A: BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006, 43: 1-67. 10.1080/10408360500295626.CrossRefPubMed Thomadaki H, Scorilas A: BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006, 43: 1-67. 10.1080/10408360500295626.CrossRefPubMed
15.
go back to reference Hanada M, Aimé-Sempé C, Sato T, Reed JC: Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem. 1995, 270: 11962-11969. 10.1074/jbc.270.20.11962.CrossRefPubMed Hanada M, Aimé-Sempé C, Sato T, Reed JC: Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem. 1995, 270: 11962-11969. 10.1074/jbc.270.20.11962.CrossRefPubMed
16.
go back to reference Zivny J, Klener P, Pytlik R, Andera L: The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des. 2010, 16: 11-33. 10.2174/138161210789941883.CrossRefPubMed Zivny J, Klener P, Pytlik R, Andera L: The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des. 2010, 16: 11-33. 10.2174/138161210789941883.CrossRefPubMed
17.
go back to reference McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989, 57: 79-88. 10.1016/0092-8674(89)90174-8.CrossRefPubMed McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989, 57: 79-88. 10.1016/0092-8674(89)90174-8.CrossRefPubMed
18.
go back to reference Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995, 71: 1003-1007. 10.1038/bjc.1995.193.PubMedCentralCrossRefPubMed Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995, 71: 1003-1007. 10.1038/bjc.1995.193.PubMedCentralCrossRefPubMed
19.
go back to reference Laudanski J, Chyczewski L, Niklińska WE, Kretowska M, Furman M, Sawicki B, Nikliński J: Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma. 1999, 46: 25-30.PubMed Laudanski J, Chyczewski L, Niklińska WE, Kretowska M, Furman M, Sawicki B, Nikliński J: Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma. 1999, 46: 25-30.PubMed
20.
go back to reference Schorr K, Li M, Krajewski S, Reed JC, Furth PA: Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia. 1999, 4: 153-164. 10.1023/A:1018773123899.CrossRefPubMed Schorr K, Li M, Krajewski S, Reed JC, Furth PA: Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia. 1999, 4: 153-164. 10.1023/A:1018773123899.CrossRefPubMed
21.
go back to reference Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L: High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998, 9: 159-165. 10.1023/A:1008255511404.CrossRefPubMed Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L: High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998, 9: 159-165. 10.1023/A:1008255511404.CrossRefPubMed
22.
go back to reference Ramsay JA, From L, Kahn HJ: bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995, 8: 150-154.PubMed Ramsay JA, From L, Kahn HJ: bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995, 8: 150-154.PubMed
23.
go back to reference Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, Karczewska E, Marlicz K, Stachura J, Hahn EG: Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther. 2001, 15: 989-999. 10.1046/j.1365-2036.2001.01003.x.CrossRefPubMed Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, Karczewska E, Marlicz K, Stachura J, Hahn EG: Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther. 2001, 15: 989-999. 10.1046/j.1365-2036.2001.01003.x.CrossRefPubMed
24.
go back to reference Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC: Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol. 1996, 149: 1449-1457.PubMedCentralPubMed Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC: Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol. 1996, 149: 1449-1457.PubMedCentralPubMed
25.
go back to reference Lauwers GY, Scott GV, Karpeh MS: Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer. 1995, 75: 2209-2213. 10.1002/1097-0142(19950501)75:9<2209::AID-CNCR2820750904>3.0.CO;2-M.CrossRefPubMed Lauwers GY, Scott GV, Karpeh MS: Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer. 1995, 75: 2209-2213. 10.1002/1097-0142(19950501)75:9<2209::AID-CNCR2820750904>3.0.CO;2-M.CrossRefPubMed
26.
go back to reference Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP: Prognostic significance of bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis. 2003, 18: 518-525. 10.1007/s00384-003-0491-2.CrossRefPubMed Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP: Prognostic significance of bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis. 2003, 18: 518-525. 10.1007/s00384-003-0491-2.CrossRefPubMed
27.
go back to reference Richardson A, Kaye SB: Pharmacological inhibition of the bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008, 1: 244-254.CrossRefPubMed Richardson A, Kaye SB: Pharmacological inhibition of the bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008, 1: 244-254.CrossRefPubMed
28.
go back to reference Apte SS, Mattei MG, Olsen BR: Mapping of the human BAX gene to chromosome 19q13.3–q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics. 1995, 26: 592-594. 10.1016/0888-7543(95)80180-T.CrossRefPubMed Apte SS, Mattei MG, Olsen BR: Mapping of the human BAX gene to chromosome 19q13.3–q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics. 1995, 26: 592-594. 10.1016/0888-7543(95)80180-T.CrossRefPubMed
29.
go back to reference Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993, 74: 609-619. 10.1016/0092-8674(93)90509-O.CrossRefPubMed Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993, 74: 609-619. 10.1016/0092-8674(93)90509-O.CrossRefPubMed
30.
go back to reference Komatsu K, Suzuki S, Shimosegawa T, Miyazaki JI, Toyota T: Cre-loxP-mediated bax gene activation reduces growth rate and increases sensitivity to chemotherapeutic agents in human gastric cancer cells. Cancer Gene Ther. 2000, 7: 885-892. 10.1038/sj.cgt.7700181.CrossRefPubMed Komatsu K, Suzuki S, Shimosegawa T, Miyazaki JI, Toyota T: Cre-loxP-mediated bax gene activation reduces growth rate and increases sensitivity to chemotherapeutic agents in human gastric cancer cells. Cancer Gene Ther. 2000, 7: 885-892. 10.1038/sj.cgt.7700181.CrossRefPubMed
31.
go back to reference Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell. 1994, 78: 539-542. 10.1016/0092-8674(94)90518-5.CrossRefPubMed Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell. 1994, 78: 539-542. 10.1016/0092-8674(94)90518-5.CrossRefPubMed
32.
go back to reference Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I, Napolitano M, Albonici L, Vincenzoni A, Gallucci M, Frati L, Agliano AM: Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer. 1996, 69: 100-104. 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4.CrossRefPubMed Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I, Napolitano M, Albonici L, Vincenzoni A, Gallucci M, Frati L, Agliano AM: Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer. 1996, 69: 100-104. 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4.CrossRefPubMed
33.
go back to reference Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996, 12: 1055-1062.PubMed Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996, 12: 1055-1062.PubMed
34.
go back to reference Reed E: Cisplatin. Cancer Chemother Biol Response Modif. 1999, 18: 144-151.PubMed Reed E: Cisplatin. Cancer Chemother Biol Response Modif. 1999, 18: 144-151.PubMed
35.
go back to reference Vousden KH, Lu X: Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002, 2: 594-604. 10.1038/nrc864.CrossRefPubMed Vousden KH, Lu X: Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002, 2: 594-604. 10.1038/nrc864.CrossRefPubMed
36.
go back to reference Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004, 303: 1010-1014. 10.1126/science.1092734.CrossRefPubMed Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004, 303: 1010-1014. 10.1126/science.1092734.CrossRefPubMed
37.
go back to reference Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene. 2003, 22: 9030-9040. 10.1038/sj.onc.1207116.CrossRefPubMed Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene. 2003, 22: 9030-9040. 10.1038/sj.onc.1207116.CrossRefPubMed
38.
go back to reference Zhu Y, Alvarez C, Doll R, Kurata H, Schebye XM, Parry D, Lees E: Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol. 2004, 24: 6268-6277. 10.1128/MCB.24.14.6268-6277.2004.PubMedCentralCrossRefPubMed Zhu Y, Alvarez C, Doll R, Kurata H, Schebye XM, Parry D, Lees E: Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol. 2004, 24: 6268-6277. 10.1128/MCB.24.14.6268-6277.2004.PubMedCentralCrossRefPubMed
39.
go back to reference Moon M, Um SJ, Kim EJ: CAC1 negatively regulates RARα activity through cooperation with HDAC. Biochem Biophys Res Commun. 2012, 427: 41-46. 10.1016/j.bbrc.2012.08.142.CrossRefPubMed Moon M, Um SJ, Kim EJ: CAC1 negatively regulates RARα activity through cooperation with HDAC. Biochem Biophys Res Commun. 2012, 427: 41-46. 10.1016/j.bbrc.2012.08.142.CrossRefPubMed
Metadata
Title
CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line
Authors
Qi Zheng
Ling-Yu Zhao
Ying Kong
Ke-Jun Nan
Yu Yao
Zi-Jun Liao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-5

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue